Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLEVIPREX vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
For the reduction of blood pressure when oral therapy is not feasible or desirable,For the management of perioperative hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Rapidly metabolized by esterases in the blood and extravascular tissues to an inactive carboxylic acid metabolite (H152/81). Not primarily dependent on hepatic CYP450 enzymes.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
87–97% bound to plasma proteins (primarily albumin)
92-98% bound to plasma proteins (primarily albumin)
0.32 L/kg (approx. 22 L for 70 kg); indicates limited extravascular distribution
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Intravenous: 100% (only route administered)
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No dose adjustment required for renal impairment. Clevidipine is not removed by dialysis.
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Use with caution in moderate impairment (Child-Pugh B); consider lower initial doses and titrate slowly.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients. No FDA-approved dosing recommendations.
Not recommended for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment required. Elderly patients may be more sensitive to hypotensive effects; use lower initial doses and titrate cautiously.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
None.
No FDA black box warning.
Use caution in patients with heart failure, as beta-blocker withdrawal may exacerbate angina; continue beta-blocker therapy.,Hypotension and reflex tachycardia may occur; monitor blood pressure and heart rate closely.,Can cause acute kidney injury or worsening of renal function in at-risk patients.,Lipid emulsion formulation; use caution in patients with severe hypertriglyceridemia or lipid metabolism disorders.,Contains soybean oil and egg lecithin; contraindicated in patients with allergies to soybeans or eggs.,Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to clevidipine or any component of the formulation (including soybean oil or egg lecithin),Severe aortic stenosis (may reduce cardiac output and worsen symptoms),Patients with defective lipid metabolism (e.g., hyperlipoproteinemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
No specific food interactions; administer IV only. The lipid emulsion contains soybean oil and egg lecithin; contraindicated in patients with allergies to soy or eggs. No oral intake required.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, maternal toxicity at high doses led to fetal effects (reduced fetal weight, delayed ossification). First trimester: limited data; risk cannot be excluded. Second and third trimesters: may cause fetal acidosis, hypotension, and bradycardia due to maternal hypotension. Use only if potential benefit justifies potential risk.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
No data on presence in human milk or effects on breastfed infants. Clevidipine is highly protein-bound (>99%) and rapidly metabolized, suggesting minimal excretion into milk. However, caution is advised. M/P ratio: not determined.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No specific dose adjustments studied in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect clearance, but no data. Use lowest effective dose and shortest duration. Titrate to effect with caution, as pregnant patients may have increased sensitivity to hypotensive effects.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
CLEVIPREX (clevidipine) is an ultrashort-acting dihydropyridine calcium channel blocker for IV use in perioperative hypertension. Onset within 2-4 minutes, half-life ~1 minute. Titrate every 5-10 minutes; avoid in severe aortic stenosis, heart failure with reduced ejection fraction, and lipid disorders (formulated in lipid emulsion). Monitor for reflex tachycardia. Use aseptic technique; discard unused portion after 12 hours.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
This medication is given intravenously to rapidly lower blood pressure during surgery or in hospital settings.,You will be closely monitored for heart rate and blood pressure changes during infusion.,Report any symptoms like chest pain, shortness of breath, or irregular heartbeat immediately.,Do not stop or adjust the infusion on your own; it is controlled by healthcare staff.,Inform your doctor if you have any allergies to eggs, soybeans, or lipids.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLEVIPREX vs AFEDITAB CR, answered by our medical review team.
CLEVIPREX is a Calcium Channel Blocker that works by Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLEVIPREX and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLEVIPREX is: Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLEVIPREX and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLEVIPREX is classified as Category C. Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinical. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.